Lower risk patients that required hypomethylating agents a multicentric experience from latin-america

IASTREBNER, MARCELO; BELLI, CAROLINA; LAZZARINO, CAROLINA; FANTL, DOROTEA; PINTOS, NOEMÍ; BENGIÓ, RAQUEL; PRATES, M VIRGINIA; ROSENHAIN, MARIANA; POSSE COBARCO, JUAN; CELEBRIN, LUCIA; MORO, DIEGO; GARCÍA RIVELLO, HERNÁN; GRILLÉ, SOFÍA; FLORES, GABRIELA; RIVAS, MARÍA M; ENRICO, ALICIA; ABELLO POLO, VIRGINIA; ARAUJO SCHUSTER, SERGIO; ARBELBIDE, JORGE

Valencia

Simposio; 14th Symposium on Myelodysplastic Syndromes; 2017

Myelodysplastic Foundation

Hypomethylating agents (HMA), azacitidine and decitabine are being adopted in lower-risk patient with transfusion dependence, or, during the follow-up according to worsening clinical features. In this sub-analysis, our aim was to examine the outcomes of Latin-American MDS with a basal lower-risk category that underwent HMA treatment during their follow-up. Methods: We selected 112 (51%) patients from a multicentric retrospective Latin-American database of 221 who were under treatment between November-07/January-17. Lower Risk patients were diagnosed between May-05/August-16 and classified according to the 89-IPSS and 23-CPSS (for CMML) (p=0.172).Results: Lower-risk patients showed a median age of 71 (20-89) years, 76% >60 years, 59% males, 62% performance status >0, 54% with co-morbidities, 76% hemoglobin level 4% (p=0.028), hemoglobin